The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Bronchiolitis Obliterans Syndrome Market Expected To Reach Based On Its 2026 Value?
The market for bronchiolitis obliterans syndrome has demonstrated robust expansion over recent years. It is anticipated to increase from $1.59 billion in 2025 to $1.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. The historical rise in this market can be attributed to factors such as the growth in organ transplantation, an increase in chronic graft rejection cases, improved hospital pulmonary care, the extensive use of immunosuppressants, and the limitations associated with early diagnostics.
The bronchiolitis obliterans syndrome market is anticipated to show robust growth in the coming years. It is projected to reach $2.43 billion by 2030, with a compound annual growth rate (CAGR) of 8.7%. This expected growth during the forecast period is largely driven by an increase in transplant procedures, advancements in early detection technologies, the emergence of personalized immunotherapy, the development of specialty respiratory centers, and more effective long-term patient management. Significant trends for the forecast period include intensified monitoring following transplantation, the expansion of immunosuppressive therapies, broader early diagnostic testing, a concentrated effort on preserving long-term lung function, and an increasing demand for specialized pulmonary care.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24488&type=smp
Which Strong Drivers Are Impacting The Bronchiolitis Obliterans Syndrome Market Growth?
The expansion in lung transplant procedures is anticipated to fuel the future growth of the bronchiolitis obliterans syndrome market. A lung transplantation involves a surgical intervention to substitute a compromised or dysfunctional lung with a healthy donor lung, thereby enhancing respiratory function. The rise in these transplantations can be attributed to progress in surgical methodologies, which have substantially elevated success rates and minimized complications, rendering the operation safer and more reachable for patients who require it. This procedure effectively manages advanced bronchiolitis obliterans syndrome by substituting diseased lungs with healthy ones, thereby improving both breathing and overall lung function. As an illustration, in January 2025, data from the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational entity, indicated that lung transplants experienced their most significant proportional increase, rising from 3,026 procedures in 2023 to 3,340 in 2024, representing a 10.4 percent surge. Consequently, the increasing volume of lung transplants is a primary impetus for the expansion of the bronchiolitis obliterans syndrome market.
Which Segment Classifications Are Used In The Bronchiolitis Obliterans Syndrome Market Segment Analysis?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
Which Trends Are Guiding The Direction Of The Bronchiolitis Obliterans Syndrome Market?
Major companies operating in the bronchiolitis obliterans syndrome market are concentrating on creating advanced solutions, such as at-home nebulized therapy, to improve medication adherence and inhibit disease progression through focused, continuous treatment. At-home nebulized therapy involves the use of a nebulizer to convert liquid medication into an inhalable mist, ensuring direct delivery to the lungs. This convenient, self-administered treatment allows for the effective management of respiratory conditions from the comfort of one’s home. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, introduced ARINA-1, which was granted Food and Drug Administration (FDA) Fast Track Designation for its objective of preventing the progression of bronchiolitis obliterans syndrome (BOS) in patients who have undergone bilateral lung transplants. This significant regulatory achievement highlights ARINA-1’s potential to address a crucial unfulfilled medical need in transplant medicine. The Fast Track status facilitates more frequent communication with the FDA and gives priority to ARINA-1 for accelerated development and review, reflecting Renovion’s dedication to advancing respiratory health through innovative, patient-centric therapeutics.
Which Firms Are Contributing To The Bronchiolitis Obliterans Syndrome Market Ecosystem?
Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.
Get The Full Bronchiolitis Obliterans Syndrome Market Report:
Which Region Holds The Highest Market Share In The Bronchiolitis Obliterans Syndrome Market?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Bronchiolitis Obliterans Syndrome Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Bronchiolitis Obliterans Syndrome Market 2026, By The Business Research Company
Bronchitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/bronchitis-treatment-global-market-report
Reversible Airway Diseases Treatment Market Report 2026
Tracheitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model